IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.

Journal:
Circulation
Published:
DOI:
10.1161/circulationaha.125.074041
Affiliations:
15
Authors:
25
Go to article
Institutions Authors Share
University of Oxford, United Kingdom (UK)
6.900000
 0.28
John Radcliffe Hospital, United Kingdom (UK)
5.033333
 0.20
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)
5.000000
 0.20
Imbria, United States of America (USA)
2.500000
 0.10
Oxford University Hospitals NHS Trust (OUH), United Kingdom (UK)
1.700000
 0.07
Aarhus University (AU), Denmark
1.000000
 0.04
UCL, United Kingdom (UK)
1.000000
 0.04
Imperial College London (ICL), United Kingdom (UK)
1.000000
 0.04
Institute of Measurement Science (IMS), SAS, Slovakia
0.333333
 0.01
Bern University Hospital, Switzerland
0.333333
 0.01
University of Birmingham, United Kingdom (UK)
0.200000
 0.01
Interested in Cardiovascular Medicine and Haematology?